N/A N=150 Webnovela for Hispanic Dementia Family Caregivers
Alzheimer's Disease · Dementia
Primary: Stress on the Perceived Stress Scale — 14.57; 15.37 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=22 Efficacy of Scleral Contact Lenses for Daily Wear for Regular and Irregular Refractive Errors Compared to Habitually Worn Scleral Lenses
Scleral Lens Wearers
Primary: The Primary Endpoint of the Study is the Overall Satisfaction and Desire to Continue Wearing the Study Lenses — 15; 2; 4 Participants
N/A N=87 A Study To Describe The Real World Use Of Bosutinib In The UK And Netherlands
Chronic Myeloid Leukaemia
Primary: Percentage of Participants With Cumulative Complete Haematological Response (CHR) — 93 percentage of participants
Phase 4 N=40 Topical Steroid Formulation and Wet Wraps
Dermatitis, Atopic
Primary: Efficacy of 0.1% Triamcinolone Containing Wet Wrap as an Ointment or as a Cream Formulation in Patients With Moderate to Severe Atopic Dermatitis — 0.717; 0.589 units on…
Phase 3 N=308 A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes
Diabetes · Diabetes Mellitus, Type 2
Primary: Number of Treatment Emergent Adverse Events (TEAEs) — 228; 197; 186 Number of events
N/A N=3 Continuous Glucose Monitoring to Assess Glycemia in Chronic Kidney Disease - Changing Glucose Management
Chronic Kidney Diseases · Type 2 Diabetes
Primary: Glucose Time in Range — 495.2; 573.3 minutes per day
N/A N=18 Quantification of Intramyocardial Lipid by Proton Magnetic Resonance Spectroscopy
Heart Transplantation
Primary: Correlation Co-efficient Between MRS Spectroscopy and Endomyocardial Biopsy in Heart Transplant Participants — 0.97 correlation co-efficient — p=<0.05
Phase 2 N=54 Cyclosporine A in Combination With Abacavir Sulfate, Lamivudine, and Zidovudine and Lopinavir/Ritonavir in HIV
HIV Infections
Primary: Levels of Proviral DNA in Peripheral Blood Mononuclear Cells (PBMC) (log10) — 1.88; 1.92 log10(copies/mL)
Phase 3 N=38 Pharmacokinetics (PK) and Safety of Subgam-VF in Primary Immunodeficiency Diseases
Primary Immune Deficiency Disorders · Common Variable Immunodeficiency · X-linked Agammaglobulinaemia
Primary: Data (Derived From Absolute Concentration) Were Pooled With Historical Data and a Treatment Variable Defined (Subgam-VF or Gammaplex 5% IGIV). Outcome Measure Defined as…
Phase 2 N=208 A Study of Tarceva (Erlotinib) as First Line Therapy in Participants With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor (EGFR) Mutations
Non-Squamous Non-Small Cell Lung Cancer
Primary: Progression-free Survival Per RECIST, v. 1.1 (PFS1) — 11.000 months
Phase 2 N=415 A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide
Diabetes · Diabetes Mellitus, Type 2
Primary: HbA1c — -0.5; -0.6; -0.9; -1.0 Percentage (%) of HbA1c — p=<0.0001
Phase 2 N=41 An Efficacy and Safety Study of Mongersen (GED-0301) in Subjects With Active Ulcerative Colitis
Colitis, Ulcerative
Primary: Percentage of Participants Who Achieved Clinical Remission in the Modified Mayo Score (MMS) at Week 8 — 17.1 percentage of participants
Phase 3 N=864 Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
Kidney Cancer
Primary: Disease-free Survival — 192; 197 Participants — p=0.737
Phase 3 N=572 Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
Chronic Plaque Psoriasis · Psoriasis
Primary: Percentage of Participants Who Achieved a 75% Reduction in Psoriasis Area and Severity Index (PASI) (PASI 75) Scores at Week 16 — 80.1; 79.0 percentage of participants
N/A N=28 Electrical Stimulation for the Treatment of Post-Stroke Shoulder Pain
Shoulder Pain
Primary: Pain Intensity (Trial Stage) — 8.2; 6.1; 5.0; 2.1 score on a scale